• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

    11/15/24 4:20:24 PM ET
    $ME
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ME alert in real time by email
    SC 13D/A 1 gsk-sc13da_111224.htm AMENDMENT TO THE SCHEDULE 13D

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

     

     

    SCHEDULE 13D

    (Amendment No. 3) *

     

    INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO 240.13d-2(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934

     

    23ANDME HOLDING CO.

    (Name of Issuer)

     

    Class A Common Stock, par value $0.0001 per share

    (Title of Class of Securities)

     

    90138Q306

    (CUSIP Number)

     

    Victoria A. Whyte

    GSK plc

    79 New Oxford Street

    London

    WC1A 1DG

    United Kingdom

    Telephone: +44 (0)208 047 5000

    (Name, Address and Telephone Number of Person
    Authorized to Receive Notices and Communications)

     

    November 12, 2024

    (Date of Event which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

     

    Note: Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See §240.13d-7 for other parties to whom copies are to be sent.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act.

     

     

     
    CUSIP No. 90138Q30613D/A3Page 2 of 6

     

    1.   NAMES OF REPORTING PERSONS I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)

    GSK plc
    2.  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
    (see instructions)
    (a) ☐

    (b) ☐

    3.   SEC USE ONLY
    4.   SOURCE OF FUNDS (see instructions)

    OO
    5.   CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT TO ITEMS 2(d) or 2(e) ☐
    6.   CITIZENSHIP OR PLACE OF ORGANIZATION

    England and Wales

    NUMBER OF SHARES
    BENEFICIALLY OWNED BY
    EACH REPORTING PERSON
    WITH
      7.   SOLE VOTING POWER
    1,983,025 (1)
      8.   SHARED VOTING POWER

    0
      9.   SOLE DISPOSITIVE POWER

    1,983,025 (1)
      10.   SHARED DISPOSITIVE POWER

    0

    11.   AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    1,983,025 (1)
    12.   CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES
    (see instructions) ☐
    13.  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

    9.5% (2)

    14.   TYPE OF REPORTING PERSON (see instructions)

    CO

     Footnote

    (1) Represents shares of the Issuer’s Class A common stock, par value $0.0001 per share (the “Class A Common Stock”) that may be obtained upon the conversion of shares of Class B Common Stock (“Class B Common Stock”) held by the reporting persons. Class B Common Stock, which is not registered under the Securities Exchange Act of 1934, as amended, is convertible into shares of Class A Common Stock at the option of the holder on a share-for-share basis.

     

    (2) The percentage reported herein is based upon (i) 19,011,874 shares of Class A Common Stock of 23andMe Holding Co. (the “Issuer”) outstanding as of October 31, 2024, as reported in the Issuer’s Form 10-Q furnished with the Securities and Exchange Commission (the “SEC”) on November 12, 2024, and (ii) 1,983,025shares of Class B Common Stock held directly by Glaxo Group Limited (“GGL”), an indirect wholly owned subsidiary of GSK plc ("GSK"). Effective October 16, 2024, the Issuer completed a 1-for-20 reverse stock split of its Class A Common Stock and Class B Common Stock. All share and conversion amounts reported herein have been adjusted to reflect the reverse stock split.

     

     
    CUSIP No. 90138Q30613D/A3Page 3 of 6

     

    Item 1. Security and Issuer.

     

    This Amendment No. 3 to Schedule 13D (this “Statement”) amends and supplements the statement on Schedule 13D originally filed on November 4, 2022, as amended on January 20, 2023 and February 9, 2024 (the “Schedule 13D”) with respect to the Class A Common Stock of the Issuer, a Delaware incorporated company. GSK is filing this amendment to disclose its new percentage beneficial ownership in the Issuer, which has been decreased as a result of an increase in the outstanding Class A Common Stock of the Issuer. The Issuer’s principal executive offices are located at 223 N. Mathilda Avenue, Sunnyvale, California 94086.

     

    Item 2.  Identity and Background.

    The response set forth in Item 2 of the Schedule 13D is hereby amended by deleting Schedule 1 in its entirety and replacing it with Schedule 1 attached.

     

    Item 5. Interest in Securities of the Issuer.

     

    The response set forth in Items 5 (a) of the Schedule 13D is hereby amended by deleting the previous response in its entirety and replacing it with the following:

      

      a. GSK beneficially owns 1,983,025 shares of Class B Common Stock, which represents 9.5% of the 19,011,874 shares of Class A Common Stock of the Issuer outstanding as of October 31, 2024, as reported in the Issuer’s Form 10-Q on November 12, 2024 and the 1,983,025shares of Class B Common Stock held by GGL.

     

     
    CUSIP No. 90138Q30613D/A3Page 4 of 6

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Statement is true, complete and correct.

     

    Date: November 14, 2024

     

      GSK plc  
         
      By: /s/ Victoria A. Whyte  
      Name: Victoria A. Whyte  
      Title: Authorized Signatory  

     

     
    CUSIP No. 90138Q30613D/A3Page 5 of 6

     

    Schedule 1

     

    Name

     

    Business Address

     

    Principal Occupation or Employment

     

    Citizenship

    Board of Directors            
                 
    Sir Jonathan Symonds CBE  

    79 New Oxford Street
    London, WC1A 1DG

    United Kingdom

      Chair and Company Director   British
    Emma Walmsley  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Executive Director   British
    Julie Brown  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   British

    Elizabeth McKee

    Anderson

     

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   US
    Charles Bancroft  

    79 New Oxford Street,

    London, WC1A 1DG,

    United Kingdom

      Company Director   US
    Dr. Hal Barron  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   US
    Dr. Anne Beal  

    79 New Oxford Street

    London, WC1A 1DG

    England

      Company Director   US
    Wendy Becker  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   British & US & Italian
    Dr. Harry (Hal) Dietz  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   US
    Dr. Jesse Goodman  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   US
    Jeannie Tsun-Huei Lee  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   US
    Dr. Vishal Sikka  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Company Director   US

     

     

     
    CUSIP No. 90138Q30613D/A3Page 6 of 6

     

    Name

     

    Business Address

     

    Principal Occupation or Employment

     

    Citizenship

    GSK Leadership Team            
                 
    Emma Walmsley  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Chief Executive Officer   British
    Julie Brown  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Chief Financial Officer   British
    Diana Conrad  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Chief People Officer  

    Canadian

     

    James Ford  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      SVP and Group General Counsel, Legal and Compliance   British & US
    Sally Jackson  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      SVP, Global Communications and CEO Office   British
    Luke Miels  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Chief Commercial Officer   Australian
    Shobana Ramakrishnan  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Chief Digital & Technology Officer   US
    David Redfern  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      President, Corporate Development   British
    Regis Simard  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      President, Global Supply Chain   French & British
    Philip Thomson  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      President, Global Affairs   British
    Deborah Waterhouse  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      CEO, ViiV Healthcare and President Global Health, GSK   British
    Tony Wood  

    79 New Oxford Street

    London, WC1A 1DG

    United Kingdom

      Chief Scientific Officer   British

     

     

    Get the next $ME alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ME

    DatePrice TargetRatingAnalyst
    11/29/2022$7.00Buy
    Berenberg
    9/22/2022$6.00Outperform
    Cowen
    2/11/2022$14.00 → $11.00Outperform
    Credit Suisse
    12/20/2021$13.00 → $9.00Neutral
    Citigroup
    11/15/2021$12.00 → $13.00Buy → Neutral
    Citigroup
    11/11/2021$13.00 → $14.00Outperform
    Credit Suisse
    8/17/2021$13.00Outperform
    Credit Suisse
    7/12/2021$14.00Buy
    Citigroup
    More analyst ratings

    $ME
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Berenberg initiated coverage on 23andMe with a new price target

      Berenberg initiated coverage of 23andMe with a rating of Buy and set a new price target of $7.00

      11/29/22 7:24:54 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cowen initiated coverage on 23andMe with a new price target

      Cowen initiated coverage of 23andMe with a rating of Outperform and set a new price target of $6.00

      9/22/22 7:20:18 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Credit Suisse reiterated coverage on 23andMe Holding with a new price target

      Credit Suisse reiterated coverage of 23andMe Holding with a rating of Outperform and set a new price target of $11.00 from $14.00 previously

      2/11/22 8:14:04 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    SEC Filings

    See more
    • SEC Form 8-K filed by 23andMe Holding Co.

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/28/25 4:09:11 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Holding Co. filed SEC Form 8-K: Regulation FD Disclosure

      8-K - 23andMe Holding Co. (0001804591) (Filer)

      3/24/25 6:23:28 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by 23andMe Holding Co.

      10-Q - 23andMe Holding Co. (0001804591) (Filer)

      2/6/25 4:27:52 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Leadership Updates

    Live Leadership Updates

    See more
    • 23andMe Appoints Three New Independent Directors to Board

      SUNNYVALE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (the "Company" or "23andMe"), a leading human genetics and preventive health company, today announced the appointments of Andre Fernandez, Jim Frankola, and Mark Jensen, three accomplished and experienced executives, as independent members of the Company's Board of Directors (the "Board"), effective on October 28, 2024. Each of Mr. Fernandez, Mr. Frankola, and Mr. Jensen have been appointed to serve as members of the Board's Audit Committee and Compensation Committee, with Mr. Fernandez serving as the Chair of the Audit Committee and Mr. Jensen serving as the Chair of the Compensation Committee. In additio

      10/29/24 7:30:00 AM ET
      $ANSS
      $CDLX
      $LSCC
      $ME
      Computer Software: Prepackaged Software
      Technology
      Computer Software: Programming Data Processing
      Semiconductors
    • Madryn Asset Management, a Top Shareholder of SomaLogic, Issues Letter Regarding Opposition to the Company's Proposed Merger with Standard BioTools

      Files Preliminary Proxy Statement to Solicit Shareholders to Oppose the Merger Intends to Vote AGAINST the Conflict-Plagued and Excessively Dilutive Transaction, Which Stands to Unduly Benefit Certain Investors and Standard BioTools at the Expense of SomaLogic's Shareholders Notes the Current Premium for SomaLogic Shareholders, Based on the Deal's Exchange Ratio and Standard BioTools' Trading Price, is Only ~4.3% Underscores That SomaLogic Has Superior Alternatives to a Flawed Combination, Including a Standalone Path Leveraging its Considerable Cash Position and Strong Balance Sheet Madryn Asset Management, LP (collectively with its affiliates, "Madryn"), a holder of approximately 4

      12/12/23 5:31:00 PM ET
      $EXAS
      $ILMN
      $LAB
      $ME
      Medical Specialities
      Health Care
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Reza Afkhami Joins 23andMe as Chief Corporate Development Officer

      SOUTH SAN FRANCISCO, Calif., May 08, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) ("23andMe"), a leading human genetics and biopharmaceutical company, today announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company. 23andMe Therapeutics has a pipeline of genetically validated discovery and clinical programs, which it intends to advance through collaborations with pharmaceutical companies. Furthermore, 23andMe hopes to help the pharmac

      5/8/23 7:00:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • 23andMe Confirms All Potential Buyers Must Agree to Comply With Privacy Policy and Applicable Law

      SAN FRANCISCO, March 26, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (NASDAQ:ME), a leading human genetics and biotechnology company, today announced that it has received approvals from the U.S. Bankruptcy Court for the Eastern District of Missouri (the "Court") for its "first day" motions related to 23andMe's voluntary Chapter 11 petitions filed March 23, 2025, including authorization to pay employee wages and benefits and compensate certain vendors and suppliers in the ordinary course for goods and services provided and to enter into the binding term sheet for a $35 million debtor-in-possession financing facility from JMB Capital Partners (the "DIP Facility"

      3/26/25 6:57:42 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Initiates Voluntary Chapter 11 Process to Maximize Stakeholder Value Through Court-Supervised Sale Process

      Intends to use Proceedings to Conduct a Value-Maximizing Sale Process and Resolve Liabilities Company Expects to Continue Business Operations in the Ordinary Course During Proceedings; Secures Commitment for Approximately $35 Million in DIP Financing to Support Ongoing Operations No Changes to Customer Data Management and Access; Company Remains Committed to Transparency Around Customer Data Privacy; Any Buyer will be Required to Comply with Applicable Law with Respect to Treatment of Customer Data Company Announces Board and Leadership Changes to Support Restructuring and Sale Process SAN FRANCISCO, March 23, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. ("23andMe" or the "Company") (

      3/23/25 11:08:03 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Launches New Homocysteine (MTHFR-Related) Genetic Report and Accompanying Lab Test

      SAN FRANCISCO, March 21, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics company with a mission to help people access, understand, and benefit from the human genome, today released a new report on the genetics of homocysteine levels for 23andMe+ Premium members, as well as a blood test for next steps in further understanding said levels for an additional fee. One of the top 23andMe customer requested reports, it informs users if they are at a higher likelihood of developing slightly elevated homocysteine levels along with actionable lifestyle factors that can reduce their chances. Homocysteine is an amino acid that plays a key role in important process

      3/21/25 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ME
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ME
    Financials

    Live finance-specific insights

    See more

    $ME
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:48:20 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13D/A filed by 23andMe Holding Co.

      SC 13D/A - 23andMe Holding Co. (0001804591) (Subject)

      11/15/24 4:20:24 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by 23andMe Holding Co.

      SC 13G - 23andMe Holding Co. (0001804591) (Subject)

      11/13/24 6:00:29 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe Reports Second Quarter Fiscal Year 2025 Financial Results

      SUNNYVALE, Calif., Nov. 12, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME), a leading human genetics and preventive health company, reported its financial results for the second quarter of fiscal year 2025 (FY25), which ended September 30, 2024. Key Results: Improved GAAP Net Loss by 21% and Adjusted EBITDA by 26% for the same period in the prior year (see important additional information below).The 23andMe comprehensive Total Health longevity service is now available to all customers, combining whole exome genetic sequencing with bi-annual lab tests for 55+ key blood biomarkers, and expert clinicians trained in genetics-informed preventive care and health action p

      11/12/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • CORRECTION - 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- An earlier release under the same headline should have noted 23andMe Holding Co. (NASDAQ:ME) (23andMe) will report financial results for the second quarter of fiscal year 2025 (FY2025) prior to the market opening on Tuesday, November 12, 2024 (the prior release incorrectly stated the results would be reported after the market closes). The Company will webcast a conference call at 8:00 a.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23

      11/7/24 5:54:12 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • 23andMe to Report Q2 FY2025 Financial Results

      SUNNYVALE, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (NASDAQ:ME) (23andMe), a leading human genetics and biopharmaceutical company, announced today that it will report financial results for the second quarter of fiscal year 2025 (FY2025) after the market closes on Tuesday, November 12, 2024. The Company will webcast a conference call at 4:30 p.m. Eastern Time on that date to discuss the quarter's results and report on business progress. The webcast can be accessed on the day of the event at this link. A webcast replay will be available at the same address following the event. In addition, 23andMe will use the Say Technologies platform to allow retail and institutional

      11/7/24 7:30:00 AM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Kvarda Matthew

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:38:00 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 3 filed by new insider Walper Thomas B.

      3 - 23andMe Holding Co. (0001804591) (Issuer)

      3/26/25 4:35:46 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Chief Financial & Actng Ofcr Selsavage Joseph Anthony covered exercise/tax liability with 5,654 shares, decreasing direct ownership by 6% to 96,468 units (SEC Form 4)

      4 - 23andMe Holding Co. (0001804591) (Issuer)

      2/21/25 5:05:56 PM ET
      $ME
      Biotechnology: Pharmaceutical Preparations
      Health Care